2024
Race, Ethnicity, and Gender Differences in Patient Reported Well-Being and Cognitive Functioning Within 3 Months of Symptomatic Illness During COVID-19 Pandemic
Hill M, Huebinger R, Ebna Mannan I, Yu H, Wisk L, O’Laughlin K, Gentile N, Stephens K, Gottlieb M, Weinstein R, Koo K, Santangelo M, Saydah S, Spatz E, Lin Z, Schaeffer K, Kean E, Montoy J, Rodriguez R, Idris A, McDonald S, Elmore J, Venkatesh A. Race, Ethnicity, and Gender Differences in Patient Reported Well-Being and Cognitive Functioning Within 3 Months of Symptomatic Illness During COVID-19 Pandemic. Journal Of Racial And Ethnic Health Disparities 2024, 1-18. PMID: 39172356, DOI: 10.1007/s40615-024-02124-8.Peer-Reviewed Original ResearchPROMIS T-scoresPain interferenceBlack participantsWell-beingHealth-related quality of lifeNon-Hispanic white participantsCognitive functionMeasures of healthHealth-related qualityMethodsThis prospective cohort studyFollow-up surveyProspective cohort studyT-scoreQuality of lifeCOVID-19-related health outcomesLower well-beingPROMIS-29Physical functionHealth outcomesBaseline to 3Social participationWhite participantsCohort studyCOVID-19Sleep disturbanceThe association between prolonged SARS-CoV-2 symptoms and work outcomes
Venkatesh A, Yu H, Malicki C, Gottlieb M, Elmore J, Hill M, Idris A, Montoy J, O’Laughlin K, Rising K, Stephens K, Spatz E, Weinstein R, Group F. The association between prolonged SARS-CoV-2 symptoms and work outcomes. PLOS ONE 2024, 19: e0300947. PMID: 39074096, PMCID: PMC11285965, DOI: 10.1371/journal.pone.0300947.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 symptomsReturn to workAssociated with increased oddsAnalyzed self-reported dataNational cohort studySelf-reported dataLong COVIDCOVID-19 pandemicLost work timePublic health emergencyWork absenteeismMissed workdaysElectronic surveyEmployment statusSARS-CoV-2 infectionWell-being impactsOdds ratioWork lossCohort studyNumerous healthImpact of long COVIDCOVID-19Risk factorsThree-monthsHealth emergency
2023
Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial
Talasaz A, Sadeghipour P, Bakhshandeh H, Sharif-Kashani B, Rashidi F, Beigmohammadi M, Moghadam K, Rezaian S, Dabbagh A, Sezavar S, Farrokhpour M, Abedini A, Aliannejad R, Riahi T, Yadollahzadeh M, Lookzadeh S, Rezaeifar P, Matin S, Tahamtan O, Mohammadi K, Zoghi E, Rahmani H, Hosseini S, Mousavian S, Abri H, Sadeghipour P, Baghizadeh E, Rafiee F, Jamalkhani S, Amin A, Mohebbi B, Parhizgar S, Soleimanzadeh M, Aghakouchakzadeh M, Eslami V, Payandemehr P, Khalili H, Talakoob H, Tojari T, Shafaghi S, Tabrizi S, Kakavand H, Kashefizadeh A, Najafi A, Jimenez D, Gupta A, Madhavan M, Sethi S, Parikh S, Monreal M, Hadavand N, Hajighasemi A, Ansarin K, Maleki M, Sadeghian S, Barco S, Siegerink B, Spatz E, Piazza G, Kirtane A, Tassell B, Lip G, Klok F, Goldhaber S, Stone G, Krumholz H, Bikdeli B. Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial. Thrombosis And Haemostasis 2023, 123: 723-733. PMID: 36944357, DOI: 10.1055/a-2059-4844.Peer-Reviewed Original ResearchConceptsExtracorporeal membrane oxygenationArterial thrombosisMAIN OUTCOMEAtorvastatin 20Symptom onsetICU patientsFunctional statusIntensive care unit patientsCOVID-19Double-blind multicenterAdult ICU patientsCare unit patientsThrombo-inflammatory responseCoronavirus disease 2019Meaningful treatment effectPrespecified studyCause mortalityAtorvastatin useUnit patientsMembrane oxygenationFunctional outcomeDisease 2019Functional scalesPlaceboPatients
2022
Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes
INVESTIGATORS I, Sadeghipour P, Talasaz A, Barco S, Bakhshandeh H, Rashidi F, Rafiee F, Rezaeifar P, Jamalkhani S, Matin S, Baghizadeh E, Tahamtan O, Sharif-Kashani B, Beigmohammadi M, Farrokhpour M, Sezavar S, Payandemehr P, Dabbagh A, Moghadam K, Jimenez D, Monreal M, Maleki M, Siegerink B, Spatz E, Piazza G, Parikh S, Kirtane A, Van Tassell B, Lip G, Goldhaber S, Klok F, Krumholz H, Bikdeli B. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes. European Journal Of Internal Medicine 2022, 103: 76-83. PMID: 35879217, PMCID: PMC9212871, DOI: 10.1016/j.ejim.2022.06.014.Peer-Reviewed Original ResearchConceptsStandard-dose prophylactic anticoagulationPatient Health Questionnaire-2Proportion of patientsProphylactic anticoagulationIntermediate doseFunctional limitationsDepressive symptomsFunctional outcomeCOVID-19Intensive care unit hospitalizationCritically Ill PatientsMultiple organ failureSevere functional limitationsFunctional Status ScaleCoronavirus disease 2019Open labelExercise limitationAirway diseaseICU patientsOrgan failureIntensive careStatus ScaleClinical trialsGrade 3Anticoagulation